Full-Time

Regional Sales Manager

Posted on 5/9/2026

Malvern Panalytical

Malvern Panalytical

1,001-5,000 employees

No salary listed

Madhya Pradesh, India

Hybrid

Remote/Hybrid in Madhya Pradesh, India; extensive travel (>12 man-days/month).

Category
Sales & Account Management (1)
Required Skills
Sales
Lead Generation
Requirements
  • Master’s degree in Physics, Chemistry, Geology or Mining, or Bachelor’s/Master’s degree in engineering (Electronics / Metrology preferred)
  • Strong understanding of Physics and Chemistry
  • 5–10 years of B2B sales experience, preferably in analytical instrumentation, process industries, or system integrators
  • Willingness to travel extensively (expected >12 man-days per month)
Responsibilities
  • Full sales responsibility for the assigned region
  • Conduct field sales activities: prospecting, value proposition, demos, pricing, and negotiations
  • Lead and coordinate all lead-generation initiatives in the territory
  • Work closely with Customer Support to ensure timely service response and complaint resolution
  • Build and maintain strong customer relationships under LAMP and SMAP programs
  • Identify new growth opportunities and support regional marketing programs—seminars, conferences, and roadshows
  • Network with industry bodies and key influencers to enhance brand visibility
  • Support development of online/at-line process automation projects in Cement, Mining, and Steel sectors
  • Monitor cost of sale and execution to improve profitability
  • Provide inputs for commercial reviews and maintain complete project documentation
  • Ensure timely reporting of sales activities in the online CRM system
Desired Qualifications
  • MBA is an added advantage
  • Experience in process control, automation, and process technologies desirable

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Almelo, Netherlands

Founded

1971

Simplify Jobs

Simplify's Take

What believers are saying

  • Micromeritics $630M acquisition expands materials characterization leadership.
  • Creoptix acquisition boosts bioanalysis for pharma drug discovery.
  • MyStore relaunch accelerates quoting and ordering of consumables.

What critics are saying

  • Spectris integrates Micromeritics, eroding Malvern Panalytical market share.
  • Terry Kelly leadership sidelines management, triggers talent exodus.
  • Creoptix diverts R&D from core mining and battery clients.

What makes Malvern Panalytical unique

  • Mastersizer 3000+ launches AI-powered laser diffraction particle sizing.
  • Revontium introduces compact XRF spectrometer for elemental analysis.
  • Future Days 2025 spotlights battery innovation with expert speakers.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Malvern Panalytical who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Gym Membership

Mentorship Program

Professional Development Budget

Conference Attendance Budget

Training Programs

Stock Options

Company Equity

Pension Scheme

Family Planning Benefits

Fertility Treatment Support

Parental Leave

Adoption Assistance

Childcare Support

Student Loan Assistance

Relocation Assistance

Employee Discounts

Company Social Events

Company News

Malvern Panalytical
Mar 27th, 2026
Our UK Pharmaceutical Conference is coming to Birmingham - Register now.

Our UK Pharmaceutical Conference is coming to Birmingham - Register now. by Annalisa Soldani, Friday, 27th March 2026 On 3 June, Malvern Panalytical's UK Pharmaceutical Conference returns to Birmingham for its fourth year, bringing together pharmaceutical scientists focused on small molecule development, solid-state chemistry, formulation, and analytical science. Wednesday 3 June 2026 | Edgbaston Park Hotel & Conference Centre, Birmingham, UK If your work involves understanding materials, controlling solid forms, or reducing development risk, this is a great opportunity to engage directly with experts and peers facing the same challenges. With attendance limited to around 50 delegates, this is a focused, high-value event built for meaningful discussion, practical insight, and direct access to experts. Places are limited, so early registration is strongly recommended. Why you should join us. Small molecule development continues to demand more from scientific teams: shorter timelines, tighter control, better data, and greater confidence at every stage. Scientists today are under pressure to: * accelerate development without increasing risk * control solid forms and polymorphism more effectively * avoid scale-up issues that can disrupt progress * generate analytical insight that supports better decisions earlier Our agenda is designed to help you navigate these challenges. Across the day, you will hear practical case studies, expert perspectives, and application-focused talks that address the challenges development teams are dealing with right now. We won't be talking theory, but real science, real workflows, and real strategies that support better outcomes. See analytical technologies in action. Live demonstrations from Malvern Panalytical and Micromeritics will show how powerful analytical data can support decision-making across development and quality workflows. Small format, big impact. Large events can be busy, broad, and easy to get lost in. With around 50 attendees, you will have more opportunities to ask questions, join discussions, and speak directly with specialists, speakers, and peers facing similar challenges. The smaller format creates space for deeper conversations and stronger connections. This year, the event will also include poster presentations, opening up even more opportunities to exchange ideas, showcase work, and start valuable conversations with an engaged audience. Meet the speakers. We're proud to welcome a strong lineup of speakers, including: * Dr Jonathan Loughrey, Director of Chemical Development, Almac Group * Dr Yvonne Perrie (MBE), Professor in Drug Delivery, University of Strathclyde * Dr Steve Ward-Smith, Senior Technical Specialist, Malvern Panalytical * Dr Natalia Dadivanyan, Market Development Manager - Small Molecule Pharmaceuticals, Malvern Panalytical More speakers and the full agenda will be announced soon. Join us in Birmingham. Malvern Panalytical's 4th Annual UK Pharmaceutical Conference will take place on: | Wednesday 3 June 2026 | Edgbaston Park Hotel & Conference Centre, Birmingham, UK Spaces are limited so early registration is highly recommended. Register now to reserve your seat: https://events.malvernpanalytical.com/E2026-uk-pharma-conference Book your place today.

AZoM
Jun 9th, 2025
Malvern Panalytical's Future Days 2025 Illuminates the Path Forward for Battery Innovation and Sustainability

On May 21, 2025, Malvern Panalytical hosted its annual Future Days event, spotlighting the transformative trends in battery technology and recycling.

Startupticker.ch
Jun 2nd, 2025
Creoptix joins the Malvern Panalytical team in England

The acquisition of Creoptix AG, a specialist bioanalysis sensor company, enables Malvern Panalytical to expand its capabilities in support of drug discovery. The latter provides advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries.

Malvern Panalytical
Jul 22nd, 2024
Say hello to the new Malvern Panalytical MyStore

Malvern Panalytical Inc. has launched the new MyStore with a fresh new look, making it faster to quote and order Malvern Panalytical parts, consumables, accessories, and software.

MarketScreener
Jul 16th, 2024
Spectris to buy Micromeritics for $630M

Spectris Plc will acquire Georgia-based Micromeritics Instrument Corp for $630 million, with an additional deferred consideration of up to $53 million. The acquisition will expand Spectris' laboratory analytical instruments unit. Terry Kelly, CEO of Micromeritics, will become president of Spectris' Malvern Panalytical unit. Spectris expects the deal to be accretive to earnings per share in the first year post-completion.